As of 2025-10-28, the EV/EBITDA ratio of Syros Pharmaceuticals Inc (SYRS) is 0.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SYRS's latest enterprise value is -17.18 mil USD. SYRS's TTM EBITDA according to its financial statements is -95.71 mil USD. Dividing these 2 quantities gives us the above SYRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.9x - 13.6x | 11.2x |
| Forward P/E multiples | 12.3x - 20.0x | 16.2x |
| Fair Price | (8,445.51) - (9,351.35) | (9,421.03) |
| Upside | -7206166.0% - -7979070.7% | -8038525.0% |
| Date | EV/EBITDA |
| 2025-10-24 | 0.18 |
| 2025-10-23 | 0.18 |
| 2025-10-22 | 0.18 |
| 2025-10-21 | 0.18 |
| 2025-10-20 | 0.18 |
| 2025-10-17 | 0.18 |
| 2025-10-16 | 0.18 |
| 2025-10-15 | 0.18 |
| 2025-10-14 | 0.18 |
| 2025-10-13 | 0.18 |
| 2025-10-10 | 0.18 |
| 2025-10-09 | 0.18 |
| 2025-10-08 | 0.18 |
| 2025-10-07 | 0.18 |
| 2025-10-06 | 0.18 |
| 2025-10-03 | 0.18 |
| 2025-10-02 | 0.18 |
| 2025-10-01 | 0.18 |
| 2025-09-30 | 0.18 |
| 2025-09-29 | 0.18 |
| 2025-09-26 | 0.18 |
| 2025-09-25 | 0.18 |
| 2025-09-24 | 0.18 |
| 2025-09-23 | 0.18 |
| 2025-09-22 | 0.18 |
| 2025-09-19 | 0.18 |
| 2025-09-18 | 0.18 |
| 2025-09-17 | 0.18 |
| 2025-09-16 | 0.18 |
| 2025-09-15 | 0.18 |
| 2025-09-12 | 0.18 |
| 2025-09-11 | 0.18 |
| 2025-09-10 | 0.18 |
| 2025-09-09 | 0.18 |
| 2025-09-08 | 0.18 |
| 2025-09-05 | 0.18 |
| 2025-09-04 | 0.18 |
| 2025-09-03 | 0.18 |
| 2025-09-02 | 0.18 |
| 2025-08-29 | 0.18 |
| 2025-08-28 | 0.18 |
| 2025-08-27 | 0.18 |
| 2025-08-26 | 0.18 |
| 2025-08-25 | 0.18 |
| 2025-08-22 | 0.18 |
| 2025-08-21 | 0.18 |
| 2025-08-20 | 0.18 |
| 2025-08-19 | 0.18 |
| 2025-08-18 | 0.18 |
| 2025-08-15 | 0.18 |